SCYNEXIS, Inc. SCYX

Company Overview

SCYNEXIS, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of antifungal therapies for difficult-to-treat and drug-resistant fungal infections. The company operates within the biopharmaceutical and infectious disease sectors, with a strategic emphasis on novel anti-infective agents targeting invasive and recurrent fungal diseases. Its primary commercial and clinical focus has centered on ibrexafungerp, a triterpenoid antifungal agent marketed under the brand BREXAFEMME for vulvovaginal candidiasis and investigated for additional invasive fungal indications.

The company was founded in 1999 and is headquartered in Jersey City, New Jersey. SCYNEXIS evolved from an early-stage anti-infectives research company into a clinical-stage biotechnology firm specializing in antifungal therapeutics. A key strategic differentiator is its proprietary glucan synthase inhibitor platform, which differs structurally from echinocandin antifungals and is designed to provide oral and intravenous treatment options against resistant fungal pathogens. The company’s activities have included licensing, clinical development partnerships, and intellectual property monetization tied to antifungal assets.